Monday, December 02, 2024 12:54:20 PM
Never said I was fan either.
Pestell lies AND nodder lies--thats what you meant--correct??
Was definite around then--as were you--correct??
Did you want to discuss the SEC filed correspondence where nodder was trying to do that acquisition without informing shareholders??
OR--did you want to discuss the SEC filed docs that show EXACTLY what is and what is NOT included/excluded in the acquisition--as far as the IP, the lab,office contents etc?? Sure you know--there is NO prostate test included
Ever notice how odd it is--from you or MANY others. There is ZERO blame on nodder and or board--for ANY level of DD as far as "whats in the box". No blame for the structure of the deal. No blame for the lies about "fired for cause". No blame for the additional penalty/interest that those years of nodder lies cost shareholders. No blame that nodder presented ZERO evidence at the trial.
Then still--from some of your "cohorts"--how they want all the Pestell shares returned/yet they NEVER have ANY prob with all the millions of shares awarded nodder for that ruse. ODD huh??
So "just a guess" we were both around during that time. But we both have a diff version of events. SEC filed docs and SEC correspondence support my version. Good luck with your version of Pestell lied
Pestell lies AND nodder lies--thats what you meant--correct??
Was definite around then--as were you--correct??
Did you want to discuss the SEC filed correspondence where nodder was trying to do that acquisition without informing shareholders??
OR--did you want to discuss the SEC filed docs that show EXACTLY what is and what is NOT included/excluded in the acquisition--as far as the IP, the lab,office contents etc?? Sure you know--there is NO prostate test included
Ever notice how odd it is--from you or MANY others. There is ZERO blame on nodder and or board--for ANY level of DD as far as "whats in the box". No blame for the structure of the deal. No blame for the lies about "fired for cause". No blame for the additional penalty/interest that those years of nodder lies cost shareholders. No blame that nodder presented ZERO evidence at the trial.
Then still--from some of your "cohorts"--how they want all the Pestell shares returned/yet they NEVER have ANY prob with all the millions of shares awarded nodder for that ruse. ODD huh??
So "just a guess" we were both around during that time. But we both have a diff version of events. SEC filed docs and SEC correspondence support my version. Good luck with your version of Pestell lied
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
